Harvard Apparatus Regenerative Technology, INC 8-K filings

Harvard Apparatus Regenerative Technology, Inc. has entered into two bridge loan agreements with its CEO, Junli He, totaling $400,000, to provide working capital.

Harvard Apparatus Regenerative Technology, Inc. has amended its Form 8-K to correctly report a $300,000 bridge loan from CEO Junli He, due April 13, 2027, or upon a $5 million capital raise.

Harvard Apparatus Regenerative Technology announced the first patient has been treated with its Cellspan Esophageal Implant (CEI) in a Phase 1 clinical trial at the Mayo Clinic.

Harvard Apparatus Regenerative Technology, Inc. has entered into a $300,000 bridge loan agreement with its Chairman and CEO, Junli He, to provide immediate working capital.

Harvard Apparatus Regenerative Technology, Inc. announced a $0.7 million private placement of common stock and significant corporate governance enhancements, including board expansion and proposed charter amendments.

Harvard Apparatus Regenerative Technology, Inc. has entered into a private placement agreement to sell 1.25 million shares of common stock for approximately $2.0 million, alongside significant corporate governance enhancements including board expansion and shareholder rights reforms.

Harvard Apparatus Regenerative Technology, Inc. announced that its stockholders approved all six proposals at the 2025 Annual Meeting, including the election of two directors, ratification of auditors, key corporate governance amendments, and authorization for a reverse stock split.

Harvard Apparatus Regenerative Technology, Inc. announces a change in its independent registered public accounting firm, with Marcum LLP resigning and CBIZ CPAs P.C. being appointed, effective April 11, 2025.

Harvard Apparatus Regenerative Technology has entered into an exclusive distribution agreement with Health Regen for its consumer health and dietary supplement products, effective November 1, 2024.

Harvard Apparatus Regenerative Technology has appointed Mao Zhang, founder and CEO of StellarS Capital, to its Board of Directors, effective August 26, 2024.

Harvard Apparatus Regenerative Technology, Inc. has entered into a securities purchase agreement for a private placement of common stock, raising approximately $5 million.

Harvard Apparatus Regenerative Technology held its annual meeting on June 20, 2024, where stockholders elected three Class II Directors, ratified the appointment of Marcum LLP as the independent auditor, and approved executive compensation in a non-binding vote.

Harvard Apparatus Regenerative Technology, Inc. has entered into agreements to sell 367,767 shares of common stock for $1.5 million in a private placement.

Harvard Apparatus Regenerative Technology has entered into a loan agreement with its CEO, Junli He, for $500,000 to be repaid upon a future capital raise or by February 1, 2025.